SCHEMBL6495809

SCHEMBL6495809

CC(C)(C)OC(=O)NS(=O)(=O)c1ccccc1Cl

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 3/20 0.50
CA1 P00915 3/20 0.50
POLB P06746 1/20 0.50
CA7 P43166 1/20 0.50
CA14 Q9ULX7 1/20 0.50
FLT1 P17948 1/20 0.50
FLT4 P35916 1/20 0.50
KDR P35968 1/20 0.50
STS P08842 1/20 0.44
SLC1A3 P43003 1/20 0.43
SLC1A2 P43004 1/20 0.43
SLC1A1 P43005 1/20 0.43
HSP90AA1 P07900 1/20 0.43
HSP90AB1 P08238 1/20 0.43
ALDH1A1 P00352 3/20 0.43
KDM4E B2RXH2 1/20 0.43
NPC1 O15118 1/20 0.43
CA2 P00918 2/20 0.42
CA9 Q16790 2/20 0.42
PGR P06401 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3335057 0.85 POLB (0.54) CA12CA1POLBFLT1FLT4
SCHEMBL1925271 0.83 CA12 (0.51) CA12CA1CA7CA14NPC1
SCHEMBL1444497 0.83 CA1 (0.51) CA12CA1POLBCA7CA14
SCHEMBL1952095 0.81 CA1 (0.50) CA12CA1POLBCA7CA14
SCHEMBL27425236 0.81 CA12 (0.50) CA12CA1CA7CA14NPC1
SCHEMBL9789350 0.80 HTT (0.53) CA12CA1POLBFLT1FLT4
SCHEMBL9324279 0.80 POLB (0.49) CA12CA1POLBFLT1FLT4
SCHEMBL3529000 0.80 CA1 (0.57) CA12CA1CA7CA14ALDH1A1
SCHEMBL30339217 0.80 CA1 (0.57) CA12CA1CA7CA14ALDH1A1
SCHEMBL19792926 0.79 CTSK (0.48) ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6855725-B2 Excitatory amino acid receptor antagonists ELI LILLY AND COMPANY (US) 2005-02-15 US disclosed
US-20040063749-A1 Excitatory amino acid receptor antagonists BLEISCH THOMAS JOHN (US) 2004-04-01 US disclosed
EP-1351952-A2 PYRROLIDINYLMETHYL SUBSTITUTED DECAHYDROISOQUINOLINES AS EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2003-10-15 EP disclosed
WO-2002053556-A2 PYRROLIDINYLMETHYL SUBSTITUTED DECAHYDROISOQUINOLINES AS EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2002-07-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063749-A1 Excitatory amino acid receptor antagonists SLC1A2, SLC1A1, SLC1A3 CA12 2725/4885CA1 946/4885POLB 4292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.